Clinical trials: Neoplasm, Oral
Neoplasms, Colorectal Neoplasms
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
- Conditions
- Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms
- Trial name
- ALpha-T (NCT04644315)
- Testing
- Alectinib
- Where
- 29 sites in United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer, Non-Small Cell
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
This study was designed to evaluate and compare the efficacy of two dose schedules of an oral investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT00073008
- Testing
- GW572016 (lapatinib)
- Where
- 31 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- GlaxoSmithKline
Diffuse Large B-Cell Lymphoma
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- EPCORE DLBCL-4 (NCT06508658)
- Testing
- Epcoritamab, Rituximab, Lenalidomide
- Where
- 176 sites in United States, Argentina and 26 more
- Volunteers
- 379 people
- Sponsor
- Genmab
Cancer
Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors
The purpose of this study is to determine the safety and tolerability of XL765. XL765 is a new chemical entity that inhibits the kinases PI3K and mTOR.
- Trial name
- NCT00485719
- Testing
- XL765 (SAR245409)
- Where
- 4 sites in United States, Spain
- Volunteers
- 83 people
- Sponsor
- Sanofi
Ulcerative Colitis
Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy
Evaluation of the intraepithelial neoplasia detection rate in patients with long standing ulcerative colitis undergoing mucosal staining with oral methylene blue MMX tablets prior to colonoscopy.
- Trial name
- NCT01520324
- Testing
- oral delivery mucosal stain
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Cosmo Technologies Ltd
Carcinoma, Small Cell
Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma
GSK2879552 is a potent, selective, mechanism-based inactivator of Lysine Specific Demethylase 1 (LSD1)/ CoRepressor for Element-1-Silencing Transcription factor (CoREST) activity.
- Trial name
- NCT02034123
- Testing
- GSK2879552
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 29 people
- Sponsor
- GlaxoSmithKline
Pain, Analgesics, Opioid
A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.
The purpose of this study was to demonstrate the clinical equivalence of hydromorphone and morphine (immediate-release [IR] and sustained-release [SR] formulations) using the "worst pain in the past 24 hours" item of the Brief…
- Trial name
- NCT00410540
- Testing
- OROS hydromorphone HCL ; Morphine sulfate
- Volunteers
- 202 people
- Sponsor
- Alza Corporation, DE, USA
Solid Tumours
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
This is a 3 part study for patients with solid tumours. The purpose of Part A is to measure the amount of olaparib or its breakdown products in the bloodstream for up to 72 hours after eating and the effect of olaparib on QT…
- Trial name
- NCT01921140
- Testing
- Olaparib tablets, Pharmacokinetic sampling, Dietary Fasted
- Where
- 12 sites in Belgium, Denmark and 2 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Healthy Volunteers Bioavailability Study
A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.
To assess the absolute bioavailability of oral selumetinib in healthy male volunteers
- Trial name
- NCT02238782
- Testing
- selumetinib 75mg single dose, [14C] selumetinib IV solution
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01390818
- Testing
- MSC1936369B (pimasertib), SAR245409 (PI3K and mTOR inhibitor)
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 146 people
- Sponsor
- EMD Serono
Non-small Cell Lung Cancer
Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases
This is an open-label, single centre, Phase I study to determine the brain exposure of [11C]osimertinib in patients with EGFRm NSCLC with brain metastases.
- Trial name
- ODIN-BM (NCT03463525)
- Testing
- Osimertinib, [11C]osimertinib
- Where
- Sweden
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Head and Neck Cancer
A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
This is a Phase 1 / Phase 2 study of newly diagnosed patients with biopsy-proven head and neck cancer (squamous cell carcinoma) who are undergoing standard radiation therapy and treatment with cisplatin.
- Trial name
- BMX-HN (NCT02990468)
- Testing
- BMX-001, Radiation Therapy, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- BioMimetix JV, LLC
Acute Myeloid Leukemia
Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients
Extension study, pilot, single-arm, compassionate use of Hikma Azacitidine 300 mg Film coated tablets test product for the Acute Myeloid Leukaemia (AML) patients who completed Hikma bioequivalence study with protocol number…
- Trial name
- NCT06572982
- Testing
- Azacitidine
- Where
- United Arab Emirates
- Volunteers
- 20 people
- Sponsor
- Hikma Pharmaceuticals LLC
Lymphoma
An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)
This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients…
- Trial name
- NCT00127101
- Testing
- vorinostat, Comparator: bexarotene
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Oral Mucositis
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers.
- Trial name
- KEVLARx (NCT05966194)
- Testing
- RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2
- Where
- 14 sites in United States
- Volunteers
- 216 people
- Sponsor
- EpicentRx, Inc.
Prostate Cancer
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and maintaining testosterone suppression.
- Trial name
- NCT02135445
- Testing
- TAK-385, Degarelix
- Where
- 25 sites in United States, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Polycystic Ovary Syndrome
Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116
This study will be conducted in a single center, double-blind with 6 dose escalation groups to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of BAY1161116.
- Trial name
- NCT03119077
- Testing
- BAY1161116, Itraconazole
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Solid Tumors
A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body
This study will be an open label, 2 period, fixed sequence study in healthy male subjects, performed at a single study center in the Unites States of America.
- Trial name
- NCT04187456
- Testing
- Savolitinib, Midazolam
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Leukemias, Myelodysplastic Syndromes
Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
The goal of this safety/pharmacology study is to determine MTD of sapacitabine when administered in patients with advanced leukemias or myelodysplastic syndromes.
- Trial name
- NCT00380653
- Testing
- sapacitabine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.
- Trial name
- NCT05548127
- Testing
- ARV-471, Abemaciclib
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 37 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.